top of page
News and views from the Etcembly team
All Posts
Vector Laboratories partner with Etcembly to develop new novel immunotherapeutics.
We're delighted to announce a new partnership with leading antibody manufacturer Vector Laboratories, Inc
Feb 251 min read
Advancing Protein Docking with DoRIAT
Docking Run Interpretation and Annotation Tool (DoRIAT) emerges as a standout innovation
Dec 10, 20241 min read
Etcembly are finalists in the Fierce Innovation Awards
We are delighted that our generative AI platform EMLy™️ has been shortlisted as a finalist in the Fierce Innovation Awards 2024
Oct 31, 20241 min read
Etcembly and University of Surrey launch pioneering study to unlock next-generation cancer treatments from survivors
British techbio innovator Etcembly is teaming up with researchers and clinicians from the University of Surrey to launch a groundbreaking...
Oct 17, 20242 min read
Etcembly launches groundbreaking research study searching for cancer cures in survivors
British techbio innovator Etcembly has launched a groundbreaking new research study aiming to uncover new targets for cancer therapies
Oct 2, 20242 min read
Etcembly have been picked by Oliver Sims of Octopus Ventures as one of the top 13 techbio companies to watch.
Read the full story about top techbio companies here:
Aug 23, 20241 min read
Etcembly launching groundbreaking study to uncover whether cancer survivors hold the key to new cures
Etcembly launching groundbreaking study to uncover whether cancer survivors hold the key to new cures
Aug 12, 20241 min read
Could AI cure cancer?
Marc Emmer at Inc. highlights how our approach could accelerate the development of new immunotherapies. https://www.inc.com/marc-emmer/c...
Dec 2, 20231 min read
Etcembly featured in BIA TechBio 2023 report
Etcembly are showcased as one of the companies driving the UK's AI revolution.
Dec 2, 20231 min read
Interview with CEO Michelle Teng in Inside Precision Medicine
Etcembly co-founder Michelle Teng talks to Helen Albert about her journey in science
Dec 2, 20231 min read
Supporting the next generation in biotech
Discover how we're enabling our former intern Gusztav Milotay to pursue a PhD at the University of Oxford. https://www.harwellcampus.com/...
Dec 2, 20231 min read
Etcembly aims at cancer with AI-driven, rapid TCR engineering technology
Caroline Richards, BioWorld explores how our AI-driven approach is enabling TCR discovery and optimisation at unprecedented scale and speed
Dec 2, 20231 min read
Etcembly's TCR therapeutics featured in Forbes
AI expert and futurist Bernard Marr has written about Etcembly's innovative AI approach to developing TCR-based cancer therapeutics
Sep 20, 20231 min read
Etcembly's T-cell engager featured in Inside Precision Medicine
The announcment of Etcembly's picomolar affinity bispecific T-cell engager targeting PRAME, ETC-101, covered by inside Precision Medicine
Aug 23, 20231 min read
Etcembly reveals world’s first generative AI-designed T cell engager with picomolar affinity
Techbio innovator Etcembly reveals world’s first generative AI-designed bispecific T cell engager with picomolar affinity.
Aug 23, 20232 min read
Etcembly announces breakthrough in optimising TCR assets
Etcembly Announces Breakthrough in Optimising TCR Assets. Successful Financing Brings in Singapore VC iGlobe Partners.
Dec 14, 20223 min read
Etcembly Appoints Scott Cuthill as Chief Business Officer
Etcembly Appoints Scott Cuthill as Chief Business Officer. The Oxford based company is transforming TCR immunotherapy research.
Mar 15, 20222 min read
Research Complex at Harwell welcomes Etcembly
Research Complex at Harwell is delighted to welcome Etcembly.
Feb 7, 20221 min read
Etcembly establishes new lab & office space at Oxford Science Park
Immune-focused machine learning firm joins leading AI cohort on Park
Feb 7, 20223 min read
Zelluna Immunotherapy AS Announces Exclusive Research Collaboration with Etcembly Limited
Zelluna Immunotherapy AS announces an exclusive research collaboration with Etcembly Ltd to discover...
Feb 7, 20222 min read
bottom of page